Related Experiment Videos
Antithrombotic therapy for patients with stroke symptoms. Guidelines for family physicians
1University of Toronto, Ontario.
Canadian Family Physician Medecin De Famille Canadien
|September 1, 1996
Insights
Anticoagulant therapy for stroke has risks and unproven benefits. It is recommended only for patients with a cardiac source of embolism, not artery-to-artery embolism.
Area of Science:
- Neurology
- Cardiology
- Vascular Medicine
Background:
- Anticoagulant therapy is a critical intervention for stroke management.
- The risks and benefits of anticoagulation in stroke patients require careful consideration.
Observation:
- Two case reports illustrate potential complications associated with anticoagulant therapy.
- Distinguishing between embolic sources is crucial for appropriate treatment selection.
Findings:
- Antiplatelet agents are indicated for stroke due to artery-to-artery embolism.
- Anticoagulation is reserved for cases with a confirmed cardiac embolic source posing ongoing risk.
Implications:
- This review provides a rational framework for anticoagulation decisions in neurologic patients.
- Optimizing anticoagulation strategies can mitigate risks and improve stroke outcomes.
Abstract:
Anticoagulant therapy to halt or limit a potentially devastating stroke carries both risk and an unproven benefit. Two case reports highlight potential pitfalls. Antiplatelet agents are indicated for ischemia secondary to artery-to-artery embolism. Anticoagulation should be undertaken only when a demonstrated cardiac embolic source places a patient at ongoing risk of repeated embolic stroke. This article reviews rational approaches to anticoagulation for neurologic patients.